VIM and colorectal carcinoma: Treatment with specific TGF-β type1 receptor kinase inhibitors restores E-cadherin levels and partially inhibits NRP2-induced vimentin expression, suggesting NRP2 cooperates with TGF-β1 receptor to promote EMT in CRC [108].